Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A company with a CMC site change mid-review cannot treat a competitor label that just got a narrower indication as incidental context on inspection-readiness findings at a CMO. RWE evidence-strategy director must close to drop a secondary from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

DECISION RWE evidence-strategy director in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. RWE evidence-strategy director can defend Proceed under protocol from inspection-readiness findings at a CMO after a competitor label that just got a narrower indication in a Pharma & Life Sciences challenge. 2. RWE evidence-strategy director cannot defend Proceed under protocol from inspection-readiness findings at a CMO; Pause the pathway is what the extract actually supports after a competitor label that just got a narrower indication. 3. A competitor label that just got a narrower indication never reached the population in inspection-readiness findings at a CMO — reopen intake, do not close to drop a secondary. 4. Two facts in inspection-readiness findings at a CMO after a competitor label that just got a narrower indication conflict for RWE evidence-strategy director; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether inspection-readiness findings at a CMO supports the labeled claim RWE evidence-strategy director would keep. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read inspection-readiness findings at a CMO against a competitor label that just got a narrower indication and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (inspection-readiness findings at a CMO after a competitor label that just got a narrower indication). The follow-on Clinical and Evidence Strategy action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in inspection-readiness findings at a CMO, then the action for RWE evidence-strategy director - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - What changes to drop a secondary if a competitor label that just got a narrower indication is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others